Alterity Therapeutics (ATHE) Price & Analysis

Compare

296 Followers

ATHE Stock Chart & Stats

$5.01

-$0.16(-4.23%)

At close: Jan 08 4:00 PM EST

$5.01

-$0.16(-4.23%)

Day’s Range― - ―

52-Week Range$1.00 - $7.00

Previous CloseN/A

Volume131.33K

Average Volume (3M)165.15K

Market Cap

$77.79M

Enterprise Value$26.57M

Total Cash (Recent Filing)$40.66M

Total Debt (Recent Filing)$155.46K

Price to Earnings (P/E)―

Beta0.84

Next Earnings

Feb 26, 2026

EPS Estimate

-0.39

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.43

Shares Outstanding18,125,694

10 Day Avg. Volume463,515

30 Day Avg. Volume165,145

Financial Highlights & Ratios

PEG Ratio0.09

Price to Book (P/B)1.56

Price to Sales (P/S)12.18

P/FCF Ratio-5.79

Enterprise Value/Market Cap0.34

Enterprise Value/Revenue4.88

Enterprise Value/Gross Profit5.00

Enterprise Value/Ebitda-1.82

Forecast

1Y Price Target

$12.00

Price Target Upside139.52% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

Bulls Say, Bears Say

Bulls Say

Clinical TrialsAlterity announced the presentation of positive data from its Phase 2 in Multiple System Atrophy (MSA) at the 2025 International Congress of Parkinson’s Disease and Movement Disorders.

Drug EfficacyATH434 demonstrated a beneficial effect on orthostatic hypotension, with stabilization from baseline in both the 50mg and 75mg groups compared to a 6-point decline over 52 weeks for placebo.

Bears Say

Market ReactionDespite positive data and demonstration of therapeutic benefit in an extremely challenging setting in advanced MSA, ATHE shares are down ~15% which is attributed to sell-the-news and profit taking.

Alterity Therapeutics News

Alterity Therapeutics presents data from ATH434 Phase 2 trial

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System...

8d ago

ATHE

Alterity Therapeutics Reports Change in Substantial Holding by Regal Funds

The latest announcement is out from Alterity Therapeutics ( ($ATHE) ). On October 14, 2025, Alterity Therapeutics Limited...

2d ago

ATHE

Promising Phase 2 Results for ATH434 Boost Alterity Therapeutics’ Buy Rating

Analyst Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics and keeping the price target...

2d ago

ATHE

Alterity Therapeutics Reports Positive ATH434 Phase 2 Trial Results at 2025 MDS Congress

Alterity Therapeutics ( ($ATHE) ) has issued an update. Alterity Therapeutics announced positive results from their ATH434 Phase...

8d ago

ATHE

Alterity Therapeutics Sets AGM and Director Nomination Dates

The latest announcement is out from Alterity Therapeutics ( ($ATHE) ). Alterity Therapeutics Limited announced that its next...

24d ago

ATHE

Alterity Therapeutics presents ATH434-201 Phase 2 data

Alterity Therapeutics (ATHE) announced that data from the ATH434-201 randomized, double-blind Phase 2 clinical trial in Multiple System...

1M ago

ATHE

Alterity Therapeutics raises A$20M in strategic placement

Alterity Therapeutics (ATHE) received binding commitments for a capital raising of A$20M of fully paid ordinary shares to...

1M ago

ATHE

Alterity Therapeutics Initiates Trading Halt for Capital Raising Announcement

Alterity Therapeutics ( ($ATHE) ) just unveiled an update. On September 4, 2025, Alterity Therapeutics Limited announced a...

1M ago

ATHE

Alterity Therapeutics Initiates Trading Halt for Capital Raising

Alterity Therapeutics ( ($ATHE) ) has shared an announcement. On September 4, 2025, Alterity Therapeutics Limited announced a...

1M ago

ATHE

Alterity Therapeutics Ltd (ADR) trading halted, news pending

19:26 EDT Alterity Therapeutics (ATHE) Ltd (ADR) trading halted, news pending Published first on TheFly – the ultimate...

1M ago

ATHE

Alterity Therapeutics reports cash balance of A$40.66M as of June 30

“U.S. FDA Fast Track designation for ATH434 in MSA was the highlight of the recent quarter that also...

3M ago

ATHE

Buy Rating for Alterity Therapeutics: Promising Phase 2 Results and Investment Opportunity Amid Stock Price Dip

In a report released yesterday, Jason McCarthy from Maxim Group maintained a Buy rating on Alterity Therapeutics, with...

3M ago

ATHE

Alterity Therapeutics reports topline data from open-label Phase 2 ATH434 trial

Alterity announced topline data from the ATH434-202 open-label Phase 2 clinical trial in individuals with multiple system atrophy....

3M ago

ATHE

Alterity Therapeutics announces publication on MRI endpoint from bioMUSE study

Alterity Therapeutics (ATHE) announced that a neuroimaging measure developed in Alterity’s Biomarkers of Progression in Multiple System Atrophy...

3M ago

ATHE

ATHE FAQ

What was Alterity Therapeutics Ltd’s price range in the past 12 months?

Alterity Therapeutics Ltd lowest stock price was $1.00 and its highest was $7.00 in the past 12 months.

What is Alterity Therapeutics Ltd’s market cap?

Alterity Therapeutics Ltd’s market cap is $77.79M.

When is Alterity Therapeutics Ltd’s upcoming earnings report date?

Alterity Therapeutics Ltd’s upcoming earnings report date is Feb 26, 2026 which is in 132 days.

How were Alterity Therapeutics Ltd’s earnings last quarter?

Alterity Therapeutics Ltd released its earnings results on Feb 28, 2025. The company reported -$0.435 earnings per share for the quarter, missing the consensus estimate of -$0.136 by -$0.299.

Is Alterity Therapeutics Ltd overvalued?

According to Wall Street analysts Alterity Therapeutics Ltd’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Alterity Therapeutics Ltd pay dividends?

Alterity Therapeutics Ltd does not currently pay dividends.

What is Alterity Therapeutics Ltd’s EPS estimate?

Alterity Therapeutics Ltd’s EPS estimate is -0.39.

How many shares outstanding does Alterity Therapeutics Ltd have?

Alterity Therapeutics Ltd has 18,125,694 shares outstanding.

What happened to Alterity Therapeutics Ltd’s price movement after its last earnings report?

Alterity Therapeutics Ltd reported an EPS of -$0.435 in its last earnings report, missing expectations of -$0.136. Following the earnings report the stock price went down -2.326%.

Which hedge fund is a major shareholder of Alterity Therapeutics Ltd?

Currently, no hedge funds are holding shares in ATHE

Alterity Therapeutics Stock Smart Score

Neutral

Fundamentals

Return on Equity

-42.68%

Trailing 12-Months

Asset Growth

134.94%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Alterity Therapeutics Ltd

Alterity Therapeutics (ATHE) is a biotechnology company focused on developing innovative therapies for neurodegenerative diseases, particularly in the realm of protein misfolding disorders. The company operates primarily in the healthcare sector, leveraging its proprietary drug development platform to create novel treatments aimed at addressing unmet medical needs in conditions such as Alzheimer's disease and Parkinson's disease. Alterity's core pipeline includes drug candidates that target specific molecular mechanisms involved in these disorders, with the goal of improving patient outcomes and quality of life.

Alterity Therapeutics (ATHE) Earnings & Revenues

Historic Earnings Reports

ATHE Stock 12 Month Forecast

Average Price Target

$12.00

▲(139.52% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","13":"$13","3.25":"$3.25","6.5":"$6.5","9.75":"$9.75"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$12.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,3.25,6.5,9.75,13],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Oct<br/>2025","25":"Oct<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,4.569230769230769,5.188461538461539,5.807692307692308,6.426923076923077,7.046153846153846,7.665384615384616,8.284615384615385,8.903846153846153,9.523076923076925,10.142307692307693,10.76153846153846,11.380769230769232,{"y":12,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,4.569230769230769,5.188461538461539,5.807692307692308,6.426923076923077,7.046153846153846,7.665384615384616,8.284615384615385,8.903846153846153,9.523076923076925,10.142307692307693,10.76153846153846,11.380769230769232,{"y":12,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,3.95,4.569230769230769,5.188461538461539,5.807692307692308,6.426923076923077,7.046153846153846,7.665384615384616,8.284615384615385,8.903846153846153,9.523076923076925,10.142307692307693,10.76153846153846,11.380769230769232,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":6.9,"date":1654041600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.95,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.72,"date":1685577600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.17,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.52,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":3.31,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":4.8,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":3.78,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.18,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.45,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.6,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.01,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.95,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >